Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: An adjunct or an alternative to drug therapy?

Journal of Clinical Apheresis

Volumn 20, Issue 3, 2005, Pages 171-184

  Saniabadi, Abbi R ^a   Hanai, Hiroyuki ^b   Suzuki, Yasuo ^c   Ohmori, Toshihide ^d   Sawada, Koji ^e   Yoshimura, Naoki ^f   Saito, Yasushi ^f   Takeda, Yuji ^a   Umemura, Kazuo ^b   Kondo, Kazunao ^b   Ikeda, Yasuhiko ^b   Fukunaga, Ken ^g   Nakashima, Mitsuyoshi ^h   Beretta, Alberto ⁱ   Bjarnason, Ingvar ^j   Lofberg, Robert ^k  

^a JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^d Ageo Central General Hospital   (Japan)

^e Fujimoto Hospital Medicine   (Japan)

^f CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

^h Hamamatsu CPT   (Japan)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Adacolumn; CXCR3; Hepatocyte growth factor; IL 1 receptor antagonist; Inflammatory bowel disease; L selectin; Soluble TNF receptors

Indexed keywords

ANTIINFLAMMATORY AGENT; CELLULOSE ACETATE; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT RECEPTOR; CYTOKINE; FC RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASE; BONE MARROW CELL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CROHN DISEASE; CYTAPHERESIS; ENTERITIS; GRANULOCYTE; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; INTESTINE MUCOSA; LEUKAPHERESIS; MACROPHAGE; MONOCYTE; REMISSION; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASES; COLITIS, ULCERATIVE; COMPLEMENTARY THERAPIES; CROHN DISEASE; CYTOKINES; FEMALE; HUMANS; LEUKAPHERESIS; LYMPHOCYTES; MALE; PHAGOCYTES;

EID: 28444463001     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20046     Document Type: Conference Paper

References (87)

1. Taffet SL, Das KM. Sulphasalazine-adverse effects and desensitization. Dig Dis Sci 1983;28:833-842.
2. Allison MC, Dhillon AP, Lewis WG. Inflammatory bowel disease. London: Mosby; 1998. p 91-140.
3. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
4. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003;206:388-390.
5. Seegers D, Bouma G, Pena AS. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2002;16(Suppl 4):53-58.
6. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004;4:97-107.
7. Severino G, Del Zompo M. Adverse drug reactions: role of pharmacogenomics. Pharmacol Res 2004;49:363-373.
8. Clutterbuck H. On the proper administration of blood-letting for the prevention and cure of disease, London 1840. History & Special Collections. UCLA Louise M. Darling Biomedical Library.
9. Abel JJ, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmapheresis). J Pharmacol Exp Ther 1924;5:625-631.
10. Goldfinger D, Capostagno V, Lowe C, Sacks HJ, Gatti RA. Use of long-term leukapheresis in the treatment of chronic lymphocytic leukemia. Transfusion 1980;20:450-454.
11. Lazarus HM. Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion 1991;31:122-128.
12. Eshleman JR, Silberstein LE. The development of selective plasmapheresis as a means for specific therapeutic intervention (editorial). Transfusion 1991;31:96-98.
13. Saniabadi AR, Hanai H, Takeuchi K, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59.
14. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Saniabadi AR. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001;16:1-9.
15. Hanai H, Watanabe F, Saniabadi A, Matsushita I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002;47:2349 2353.
16. Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I. Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 2003;1:28-35.
17. Kanke K, Nakano M, Hiraishi H, Terano A. Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis 2004;36:512-518.
18. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid na patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-571.
19. Cohen RD. Treating ulcerative colitis without medications: "Look Mom, no drugs!" Gastroenterology 2005;128:235.
20. Saniabadi AR, Wada K, Umemura K, Sakuma S, Nakashima M. Impairment of phagocytic cell respiratory burst by UVA in the presence of fluoroquinolones: an oxygen-dependent phototoxic damage to cell surface microvilli. J Photochem Photobiol B 1996;33:137-142.
21. Rachmilewitz D (on behalf of an international study group). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 1989;298:82-86.
22. Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behcet's disease: from Hippocrates to the third millennium. Br J Ophthalmol 2003;87:1175-1183.
23. Kanekura T, Gushi A, Iwata M, Fukumaru S, Sakamoto R, Kawahara K, Maruyama I, Kanzaki T. Treatment of Behcet's disease with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2004;51:S83S87.
24. Hashida N, Ohguro N, Yamamoto S, Nakagawa Y, Tano Y. Unusual neutrophil infiltration under the soft contact lens in a patient with Behcet's disease (Engl Abstr.) Jpn J Ophthalmol 2003;47:469-472.
25. Demirkesen C, Tuzuner N, Mat C, Senocak M, Buyukbabani N, Tuzun Y, Yazici H. Clinicopathologic evaluation of nodular cutaneous lesions of Behcet syndrome. Am J Clin Pathol 2001;116:341-346.
26. Rottman JB, Smith TL, Ganley KG. Potential role of the chemokine receptors CXCR3, CXCR4, and the integrin alphaEbeta 7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-347.
27. Gillitzer R. Inflammation in human skin: a model to study chemokine-mediated leukocyte migration in vivo. J Pathol 2001;194:398-405.
28. Wakugawa M, Nakamura K, Kakinuma T, Tamaki K. CC chemokine receptor 4 as a possible target for therapy of atopic dermatitis. Drug News Perspect 2002;15:175-179.
29. Yuan YH, ten Hove T, The FO, Slors JF, van Deventer SJ, te Velde AA. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis 2001;7:281-286.
30. Biswas P, Mantelli B, Hasson H, Vecchi A, Saniabadi A, Lazzarin A, Beretta A. In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. Clin Immunol 2003;109:355-358.
31. Kanekura T, Yoshii N, Yonezawa T, Kawabata H, Saruwatari H, Kanzaki T. Treatment of pustular psoriasis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2003;49:329-332.
32. Kanekura T, Hashiguchi T, Mera Y, Katahira A, Nakamura I, Maruyama I, Kanzaki T. Improvement of SLE skin rash with granulocyte and monocyte adsorption apheresis. Dermatology 2004;208:79-80.
33. Ohmori T, Yamagiwa A, Nakamura I, Saniabadi A, Nishikawa K. Treatment of pyoderma gangrenosum associated with Crohn's disease Am J Gasroenterol 2003;98:2101-2102.
34. Mori S, Nagashima M, Yamazaki J, Yamamoto M, Hirata I, Yoshino S, Saniabadi A. Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases. Int J Dermatol 2004;43:732-735.
35. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 2003;98:511-512.
36. Poordad FF, Tran T, Martin P. Developments in hepatitis C therapy during 2000-2002. Expert Opin Emerg Drugs 2003;8:9-25.
37. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C virus. Hepatology 1996;23:695-699.
38. Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis 2003;16:587-592.
39. Sawada K, Masaki N, Hayashi S, Zenia M, Ishikawa T, Takahashi H, Ohnishi K, Fukunaga K, Hara N, Yamamoto T, Hada T, Toda G. Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-α2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia. J Vir Hepatitis 2005; (in press).
40. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.
41. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2003;7:89-105.
42. Sreenarasimhaiah J, Jaramillo A, Crippin J, Lisker-Melman M, Chapman WC, Mohanakumar T. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol 2003;64:497-504.
43. Shinohara M, Ishii K, Takamura N. Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response or no response to IFN. Hepatol Res 2003;27:260-265.
44. Cravatto M, Pozzato G, Zorat F, Pusini E, Sentini G. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites for the virus. Haematologica 2000;85:356-361.
45. Caussin-Scwemling C, Scmitt C, Stoll-Keller F. Study of the infection of human blood derived monocyte/macrophage with hepatitis C virus in vitro. J Med Virol 2001;65:14-22.
46. Bouffard P, Hayashi PH, Acevedo R, Levy N, Zeldis JB. Hepatitis C is detected in a monocyte macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 1992;166:1276-1280.
47. Hiraishi K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kashiwagi N, Saniabadi AR, Adachi M. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003;7:334-340.
48. Edwards SW, Hallett MB. Seeing the wood for the tree: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997;18:320-324.
49. Lloyd LR, Oppenheim JJ Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 1992;13:169-172.
50. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leucocyte emigration. Annu Rev Physiol 1995;57:827-872.
51. Hogg N, Berlin C. Structure and function of adhesion receptors in leucocyte trafficking. Immunol Today 1995;16:327-330.
52. Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 1998;2:134-141.
53. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-1538.
54. Lantz M, Bjornberg F, Olsson I, Richter J. Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J Immunol 1994;152:1362-1369.
55. Mohler KM, Torrance DS, Smith GA, Widmer MB. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoximia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
56. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-399.
57. Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K. Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: Evidence for the involvement of plasma IgG, complement C3 and β2 integrin. Inflamm Res 2004;53:277-283.
58. Dionne S, D'Agata ID, Hiscott J, Vanounou T, Seidman EG. Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 1998;112:435-442.
59. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-2440.
60. Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 2003;307:146-151.
61. Shand A, Forbes A. Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab? Int J Colorectal Dis 2003;18:1-11.
62. Hanauer SB. Medical therapy of ulcerative colitis. Gastroenterology 2004;126:1582-1592.
63. Egan L J, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004;126:1574-1581.
64. Tibbie JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
65. Brannigan AE, O'Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000;13:361-366.
66. McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489-493.
67. Lee, A, Whyte M, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993;54:283-288.
68. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of appoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-4428.
69. Lerebours E, Bussel A, Modigliani R, Bastit D, Florent C, Rabian C, Rene E, Soule JC. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Gastroenterology 1994;107:357-361.
70. Van Montfrans C, Rodriguez Pena MS, Pronk I, Ten Kate FJ, Te Velde AA, Van Deventer SJ. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology 2002;123:1865-1876.
71. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
72. Kashiwagi N, Saniabadi A, Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002;47:1334-1341.
73. Kourilsky P, Truffa-Bachi P. Cytokine fields and the polarization of the immune response. Trends Immunol 2001;22:502-509.
74. D'Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM. Human neutrophil Fc receptor mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 1994;100:173-179.
75. Hay FC, Nineham LJ, Perumal R, Roitt IM. Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical features. Ann Rheum Dis 1979;38:1-7.
76. Moldovan I, Galon J, Maridonneau-Parini I, Roman Roman S, Mathiot C, Fridman WH, Sautes-Fridman C. Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunol Lett 1999;68:125-134.
77. Ohkuro M, Ogura M, Kobayashi K, Sakai M, Takahashi K, Nagasawa S. Effect of iC3b binding to immune complexes upon the phagocytic response of human neutrophils: synergistic functions between Fc?R and CR3. FEBES Lett 1995;373:189-192.
78. Vogt W. Drugs and the complement system. Trends Pharmacol Sci 1985;6:114-119.
79. Ross GD, Medof ME. Membrane complement receptors specific for bound fragments of C3. Adv Immunol 1985;37:217-267.
80. Ross GD, Vetvicka V. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 1993;92:181-184.
81. Myones BL, Dalzell JG, Hogg N, Ross GD. Neutrophil and monocyte cell surface p 150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest 1988;82:640-651
82. Newman SL, Devery-Pocius JE, Ross GD, Henson PM. Phagocytosis by human monocyte-derived macrophages. Independent function of receptors for C3b (CR1) and iC3b (CR3). Complement 1984;1:213-227.
83. Marzocchi-Machado CM, Alves CM, Azzolini AE, Polizello AC, Carvalho IF, Lucisano-Valim YM Fcgamma and complement receptors: expression, role and co-operation in mediating the oxidative burst and degranulation of neutrophils of Brazilian systemic lupus erythematosus patients. Lupus 2002;11:240-248.
84. Muto S, Vetvicka V, Ross GD. CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents. J Clin Immunol 1993;13:175-184.
85. De Andres B, Mueller AL, Verbeek S, Sandor M, Lynch RG. A regulatory role for Fcgamma receptors CD16 and CD32 in the development of murine B cells. Blood 1998;92:2823-2829.
86. Sulica A, Morel P, Metes D, Herberman RB. Ig binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol 2001;20: 371-414.
87. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or- dependent ulcerative colitis. Inflamm Bowel Dis 2004;10:251-257.